Email Page Print Page

News & Media

These are news releases that are related to our Investor efforts.  Releases are listed in chronological order and are archived by year.  Sign-up to receive news as it is released via email or RSS.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011

2012 Archives

Nov 28, 2012
Financing expected to fund completion of BEMA Buprenorphine Phase 3 program and progress BNX to NDA submission
Nov 8, 2012
Positive outcome achieved from pivotal pharmacokinetic study for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence; NDA filing in 2Q 2013
Oct 15, 2012
Launch triggers final E.U. milestone payment of $2.5 million to BDSI
Aug 9, 2012
Pivotal clinical studies underway for BEMA Buprenorphine for chronic pain and BNX for opioid dependence
Aug 2, 2012
Phase 3 program includes two efficacy studies – one in opioid naïve and one in opioid experienced patient populations
Jun 28, 2012
Results of the FDA recommended trial demonstrate dose proportionality ahead of the forthcoming pivotal pharmacokinetic study versus Suboxone
May 21, 2012
Milestone payment received in conjunction with granting of first country registration and pricing approval
May 10, 2012
Signed licensing agreement with Endo Pharmaceuticals for BEMA Buprenorphine for chronic pain worth up to $180 million plus royalties
Apr 17, 2012
Patent extends exclusivity protection for BEMA Buprenorphine and BEMA Buprenorphine/Naloxone (BNX) through 2027
Apr 5, 2012
Event will focus on the treatment of Opioid Dependence and the BNX development program
Mar 19, 2012
Licensing agreement completed with Endo Pharmaceuticals for BEMA Buprenorphine worth up to $180 million plus royalties
Mar 14, 2012
Stay granted following USPTO rejection of all claims in all three MonoSol patents